Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells

BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide. The only drug currently approved for clinical use in the treatment of advanced HCC is sorafenib. However, many patients with HCC show reduced sensitivity to sorafenib during treatment. SIRT3, a member...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Hanhee, Park, Yusun, Kim, Taehun, Kim, Jisu, Lee, Jong Sook, Kim, Seon Yoo, Chung, Jee-in, Ko, Hae yong, Pyun, Jae-Chul, Kim, Kyung Sik, Lee, Misu, Yun, Mijin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168998/
https://www.ncbi.nlm.nih.gov/pubmed/32306906
http://dx.doi.org/10.1186/s12885-020-06822-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168998/
https://www.ncbi.nlm.nih.gov/pubmed/32306906
http://dx.doi.org/10.1186/s12885-020-06822-4

Ejemplares similares